Treatment Resistance Following Anti-cancer Therapies
Public ClinicalTrials.gov record NCT04436120. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
TREATMENT RESISTANCE FOLLOWING ANTI-CANCER THERAPIES (TRANSLATE)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The TRANSLATE study aims to better understand why tumors become resistant to standard anti-cancer therapies. New tumor biopsy and blood samples are collected after disease progression on standard-of-care anti-cancer treatment and compared to the initial (archival) tumor biopsy sample taken from the same patient. Annotated reports of results from clinical Next Generation Sequencing (NGS) gene panel tests of both tumor and blood are sent directly from the testing lab to the study physician for discussion with the patient during the study. Patients may participate in interventional treatment clinical trials at the same time as participating in the TRANSLATE study. Primary data will be publicly available after the study to support further research.
Study identification
- NCT ID
- NCT04436120
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 38 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 12, 2019
- Primary completion
- Dec 13, 2020
- Completion
- Dec 13, 2020
- Last update posted
- Dec 2, 2024
2019 – 2020
United States locations
- U.S. sites
- 17
- U.S. states
- 6
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Southern Cancer Center, P.C. | Daphne | Alabama | 36526 | — |
| Southern Cancer Center, PC | Mobile | Alabama | 36607 | — |
| Southern Cancer Center, PC | Mobile | Alabama | 36608 | — |
| Alaska Urological Institute dba Alaska Clinical Research Center | Anchorage | Alaska | 99503 | — |
| Arizona Oncology Associates, PC-HOPE | Tucson | Arizona | 85704 | — |
| Arizona Oncology Associates, PC - HOPE | Tucson | Arizona | 85711 | — |
| The Oncology Institute of Hope Innovation | Glendale | California | 91204 | — |
| The Oncology Institute of Hope Innovation | Long Beach | California | 90805 | — |
| UCI Medical Center-Chao Family Comprehensive Cancer Center | Orange | California | 92868-3201 | — |
| The Oncology Institute of Hope Innovation | Santa Ana | California | 92705 | — |
| Sansum Clinic | Santa Barbara | California | 93105 | — |
| Sansum Clinic | Solvang | California | 93463 | — |
| The Oncology Institute of Hope and Innovation | Whittier | California | 90602 | — |
| ICRI-Administrative and Supplies Only | Whittier | California | 90603 | — |
| Woodlands Medical Specialists PA | Pensacola | Florida | 32503 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
| University of Washington Medical Center | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04436120, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 2, 2024 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04436120 live on ClinicalTrials.gov.